[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Rhea-AI Filing Summary
On 08/04/2025, RTW Investments, LP—together with Managing Partner Dr. Roderick Wong—filed a Form 4 disclosing the purchase of 3,636,363 pre-funded warrants in Orchestra BioMed Holdings (OBIO). The warrants were acquired at $2.7499 per warrant (Transaction Code “P”) and carry a nominal exercise price of $0.0001 per share. Each warrant is immediately exercisable into one common share, but exercise is limited so total beneficial ownership does not exceed 9.99 % of OBIO’s outstanding stock.
The filing confirms RTW and Dr. Wong as >10 % shareholders and directors. Post-transaction, they hold 3.64 million derivative securities that, if fully exercised, could add an equivalent number of common shares to OBIO’s float, creating potential dilution. The warrants have no expiration date, giving the insiders flexibility on timing.
Positive
- Significant insider commitment: RTW and Dr. Wong invested roughly $10 M to increase exposure to OBIO.
- Immediate exercisability: Warrants can convert at $0.0001, indicating insiders expect long-term appreciation.
Negative
- Dilution risk: Up to 3.64 M new shares may enter the float once ownership headroom allows.
- Ownership cap: 9.99 % limit could stagger conversions, prolonging the overhang on share supply.
Insights
TL;DR: Large insider warrant buy suggests confidence but flags future dilution risk.
The acquisition of 3.64 M pre-funded warrants by RTW and Dr. Wong increases their economic exposure to OBIO without crossing the 9.99 % cap. Paying $2.75 indicates willingness to commit ~$10 M (3.64 M × $2.7499) in fresh capital, a positive signal for investors who track insider sentiment. Because the warrants are immediately exercisable at $0.0001, conversion is effectively assured once headroom exists, potentially expanding the share count by ~6 %. Investors should weigh the bullish insider stance against the dilution overhang and monitor subsequent Form 4s for exercises.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Pre-Funded Warrants (Right to Buy) | 3,636,363 | $2.7499 | $10.00M |
Footnotes (1)
- The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, together with their Attribution Parties (as defined in the Pre-Funded Warrants), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. Held by certain affiliated funds managed by RTW Investments, LP ("RTW"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein.
